Cipla Q4 results reported a 30% YoY rise in consolidated net profit to ₹1,222 crores from ₹939 crores in the fourth quarter of the previous financial year. On a full-year basis, Cipla made a net profit of ₹5,273 crores, up 28% from ₹4,106 crores in FY24.
On the Cipla results date, i.e., on May 13, Cipla share price closed at ₹1,520.10. On the next trading day, it opened with a fall at ₹1,495. In the last 5 years, the Cipla share price has delivered more than 160% returns.
Cipla Q4 Results: Revenue and Investment
- In Cipla quarterly results, the consolidated revenues for the quarter ended March 2025 stood at ₹6,730 crores, up 9% on a year-on-year basis.
- EBITDA was up by 17% to ₹1,538 crores in Q4 FY25.
- EBITDA margin improved to 22.8% as compared to 21.4% in the same period last year.
- The cash and cash equivalents rose by 31% YoY to ₹10,807 crores for the financial year ending March 31, 2025.
- R&D investments stood at ₹426 crores (6.3% of sales), driven by product filings and development efforts.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
| Particulars (in ₹ Cr) | Q4 FY25 | Q4 FY24 | YoY Change |
|---|---|---|---|
| Net Profit | 1,222 | 939 | 30% |
| Revenue from operations | 6,730 | 6,163 | 9% |
| EBITDA | 1,538 | 1,316 | 17% |
Cipla Q4 Results: Segment Performance
- One-India: One India Business grew at a healthy 8% YoY during the quarter. Branded Prescription business continued to outpace the market growth in key chronic therapies, Trade Generics is back on the growth trajectory and Anchor brands of CHL continued to grow bigger.
- North America: Delivered quarterly revenue of $221 million, supported by traction in differentiated assets.
- Emerging Markets and Europe: Posted a substantial quarterly revenue growth of 16% YoY in USD terms.
Cipla Q4 Results: Management Commentary
Umang Vohra, MD and Global CEO, Cipla Ltd, said, “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies.
Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 Mn.
In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”
Cipla Q4 Results: Dividend
Cipla has declared a final dividend of ₹13 per share and a special dividend of ₹3 per share. So, the total dividend for the financial year 2025 stood at ₹16 per share (face value of ₹2 each). The record date is fixed at June 27, 2025 while the payment date has not been announced yet.
So, open free Demat Account with SMC Global Securities to start your trading journey and stay updated with the Nifty 50 companies’ Q4 results.
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
